Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 68

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 68
---
Marketable securitiesCorporate debt securities78,007 — 78,007 — Municipal debt securities10,916 — 10,916 — U.S. government agency debt securities90,897 — 90,897 — Long-term marketable securitiesCorporate debt securities16,617 — 16,617 — Other noncurrent assetsMarketable securities - restricted (SERP)568 16 552 — Total assets at fair value$272,059 $75,070 $196,989 $— Liabilities:Contingent consideration$53,450 $— $— $53,450 Total liabilities at fair value$53,450 $— $— $53,450 Other Financial InstrumentsThe carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities.

6. Contingent Consideration

The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):December 31,2024December 31,2023Reported under the following captions in the consolidated balance sheets:Contingent consideration, current portion$47,340 $52,070 Contingent consideration, long-term— 1,380 Total$47,340 $53,450 The Company's contingent consideration liabilities are related to the USWM Acquisition in 2020 and the Adamas Acquisition in 2021. The contingent consideration liabilities are measured at fair value on a recurring basis using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement. The change in fair value is reported on the consolidated statement of earnings in Contingent consideration gain.

112

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)6. Contingent Consideration (Continued)

USWM Contingent ConsiderationOn June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises,